Search research articles
Contact Us
Filters
Showing results (21-30 of 57) with videos related to
Page
of 6
Sort By:
Arthritis Care & Research
|
November 5, 2011
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol
Saima Chohan, Michael A Becker, Patricia A MacDonald, et al.
Nucleosides, Nucleotides & Nucleic Acids
|
July 5, 2008
In memoriam: J. Edwin Seegmiller, M.D. (1920-2006)
Michael A Becker, Theodore Friedmann, Kari O Raivio, et al.
The Journal of Rheumatology
|
March 17, 2009
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout
Michael A Becker, H Ralph Schumacher, Patricia A MacDonald, et al.
ACS Nano
|
August 3, 2022
Robust Tipless Positioning Device for Near-Field Investigations: Press and Roll Scan (PROscan)
Hsuan-Wei Liu, Michael A Becker, Korenobu Matsuzaki, et al.
Nucleosides, Nucleotides & Nucleic Acids
|
July 5, 2008
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy
Michael A Becker, Patricia A MacDonald, Barbara J Hunt, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
February 20, 2016
Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment
Kenneth G Saag, Andrew Whelton, Michael A Becker, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
November 25, 2014
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy
Herbert S B Baraf, Robert A Yood, Faith D Ottery, et al.
Arthritis and Rheumatism
|
July 9, 2003
Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman
Pablo García-Pavía, Rosa J Torres, Manuel Rivero, et al.
Life Sciences
|
February 9, 2005
Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase
Yasuhiro Takano, Kumiko Hase-Aoki, Hideki Horiuchi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
August 4, 2018
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study
Kenneth G Saag, Michael A Becker, Andrew Whelton, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 57) with videos related to
Sort By:
Page
of 6
Arthritis Care & Research
|
November 5, 2011
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol
Saima Chohan, Michael A Becker, Patricia A MacDonald, et al.
Nucleosides, Nucleotides & Nucleic Acids
|
July 5, 2008
In memoriam: J. Edwin Seegmiller, M.D. (1920-2006)
Michael A Becker, Theodore Friedmann, Kari O Raivio, et al.
The Journal of Rheumatology
|
March 17, 2009
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout
Michael A Becker, H Ralph Schumacher, Patricia A MacDonald, et al.
ACS Nano
|
August 3, 2022
Robust Tipless Positioning Device for Near-Field Investigations: Press and Roll Scan (PROscan)
Hsuan-Wei Liu, Michael A Becker, Korenobu Matsuzaki, et al.
Nucleosides, Nucleotides & Nucleic Acids
|
July 5, 2008
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy
Michael A Becker, Patricia A MacDonald, Barbara J Hunt, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
February 20, 2016
Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment
Kenneth G Saag, Andrew Whelton, Michael A Becker, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
November 25, 2014
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy
Herbert S B Baraf, Robert A Yood, Faith D Ottery, et al.
Arthritis and Rheumatism
|
July 9, 2003
Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman
Pablo García-Pavía, Rosa J Torres, Manuel Rivero, et al.
Life Sciences
|
February 9, 2005
Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase
Yasuhiro Takano, Kumiko Hase-Aoki, Hideki Horiuchi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
August 4, 2018
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study
Kenneth G Saag, Michael A Becker, Andrew Whelton, et al.
Page
of 6